🇺🇸 FDA

Company profile · Sponsor

RELMADA

RELMADA THERAPEUTICS, INC.

RLMD · NYSE pharma CORAL GABLES, FL, USA
Pipeline
6
Drugs
0
Patents
7

Quick answer

RELMADA (RLMD) is a pharma company. headquartered in CORAL GABLES, FL, USA. listed on NYSE. NovaPharmaNews links 6 pipeline programs, 0 drugs, and 7 patents to this profile..

Company facts

Ticker RLMD
Exchange NYSE
Company type pharma
Headquarters CORAL GABLES, FL, USA
SEC CIK 0001553643

Pipeline (6)

Search pipeline →

  1. NDV-01 (sustained-release gemcitabine-docetaxel)

    RELMADA

    Bladder (Urothelial, Transitional Cell) Cancer

    phase 3 small molecule active

    2 trials

  2. NDV-01 (sustained-release gemcitabine-docetaxel)

    RELMADA

    Bladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive)

    phase 3 small molecule terminated

    1 trial

  3. REL-1017

    RELMADA

    Major Depressive Disorder

    phase 3 small molecule completed

    3 trials

  4. NDV01 intravesical controlled release formulation of gemcitabine and docetaxel

    RELMADA

    Non Muscle Invasive Bladder Cancer

    phase 2 small molecule active

    1 trial

  5. REL-1017

    RELMADA

    Depressive Disorder, Major

    phase 2 small molecule completed

    1 trial

  6. REL-1017

    RELMADA

    Neuropathic Pain

    phase 1 small molecule completed

    2 trials

Patents (7)

Search patents →

  1. US 11607407

    Dermal pharmaceutical compositions of 1-methyl-2′,6′-pipecoloxylidide and method of use

    Expires Mon Mar 16 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 10624887

    Compositions of (-)-17-(cyclobutylmethyl)morphinan-3,14,-diol

    Expires Mon Apr 16 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 9855226

    d-methadone for the treatment of psychiatric symptoms

    Expires Mon Dec 28 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 9468611

    d-Methadone for the treatment of psychiatric symptoms

    Expires Mon Oct 13 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 9364430

    Compositions of (-)-17-(cyclobutylmethyl)morphinan-3,14-diol

    Expires Mon Jun 09 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 9125833

    Multimodal abuse resistant and extended release opioid formulations

    Expires Mon Sep 03 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 8329744

    Methods of preventing the serotonin syndrome and compositions for use thereof

    Expires Mon Dec 06 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is RELMADA?

RELMADA (RLMD) is a pharma company. headquartered in CORAL GABLES, FL, USA. listed on NYSE. NovaPharmaNews links 6 pipeline programs, 0 drugs, and 7 patents to this profile..

What pipeline programs does RELMADA sponsor?

We track 6 ClinicalTrials.gov-linked programs for RELMADA, including NDV-01 (sustained-release gemcitabine-docetaxel) and 5 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does RELMADA company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.